Zydus Lifesciences Limited
↗Ahmedabad, India
Zydus Lifesciences Limited is an innovation-driven Indian multinational pharmaceutical company and the fourth largest pharma company in India. The company engages in research, development, production, marketing, and distribution of pharmaceutical products with a presence across the entire value chain including formulations, active pharmaceutical ingredients (APIs), vaccines, biosimilars, complex products, animal health, and consumer wellness products. Founded in 1952 and rebranded as Zydus Lifesciences in February 2022, the company has grown into a global powerhouse with operations in over 55 countries and more than 37 manufacturing facilities worldwide. With a focus on innovation in biologics, vaccines, and specialized therapeutics, Zydus serves patients across oncology, hepatology, nephrology, rheumatology, ophthalmology, immunology, and rare diseases.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Integrated Pharmaceutical Manufacturer
SIZE & FINANCIALS
Employees:10000+
Revenue:$2.7B-$3B
Founded:1952
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:Patel Family (majority shareholders)
STOCK
Exchange:NSE,BSE
Ticker:ZYDUSLIFE
Market Cap:$11.1B
PIPELINE
Stage:Phase 1|Phase 2|Phase 3|Commercial
Lead Drug Stage:Phase 3 (Saroglitazar Mg for PBC, Usnoflast for ALS)
Modalities:Small molecule, Monoclonal antibodies (mAb), Antibody-drug conjugates (ADC), Biosimilars, Fusion proteins, Vaccines (plasmid DNA, live attenuated, inactivated), Generic drugs
Active Trials:6
Trial Phases:Phase 1: 1 | Phase 2: 3 | Phase 3: 1 | Phase 4: 1
FDA Approvals:12
CORPORATE STRUCTURE
Subsidiaries:Zydus Biologics, Zydus Pharmaceuticals (USA), Zydus Pharmaceuticals (UK), Zydus Therapeutics, Zydus Wellness
Key Partnerships:Agenus: Strategic collaboration for BOT/BAL development; acquired Agenus' two biologics manufacturing facilities in Emeryville and Berkeley, CA, Bioeq: Partnership for licensing, supply and commercialization of NUFYMCO (ranibizumab biosimilar) in the US, Myriad Genetics: Agreement to commercialize MyRisk Hereditary Cancer Test, MyChoice HRD Plus, and Prolaris tests in India, Formycon: Partnership for pembrolizumab (Keytruda) biosimilar development for US market, Sterling Biotech / Perfect Day: 50% stake acquisition to enter fermentation-based protein business
COMPETITION
Position:Leader
Competitors:Dr. Reddy's Laboratories, Lupin Limited, Aurobindo Pharma, Cipla, Mankind Pharma, Torrent Pharmaceuticals, Alkem Laboratories, Biocon
LEADERSHIP
Key Executives:
Pankaj R. Patel - Chairman
Sharvil Patel - CEO and Managing Director
Punit Patel - President and Chief Executive Officer, Americas
Scientific Founders:Ramanbhai Patel, Indravadan Modi
LINKS
Website:zyduslife.com
Crunchbase:Crunchbase Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Zydus Lifesciences Limited. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.